(S)-3-Ethyl-4-[2-hydroxy-3-(2-hydroxy-acetylamino)-propoxy]-5-methyl-benzoic acid → N-((2S)-3-{2-Ethyl-4-[3-(5-isobutyl-4-methyl-pyridin-2-yl)-[1,2,4]oxadiazol-5-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide
반응식
[OH:1][NH:2][C:3]([C:5]1[CH:10]=[C:9]([CH3:11])[C:8]([CH2:12][CH:13]([CH3:15])[CH3:14])=[CH:7][N:6]=1)=[NH:4].[CH2:16]([C:18]1[CH:19]=[C:20]([CH:24]=[C:25]([CH3:37])[C:26]=1[O:27][CH2:28][C@@H:29]([OH:36])[CH2:30][NH:31][C:32](=[O:35])[CH2:33][OH:34])[C:21](O)=O)[CH3:17]>>[CH2:16]([C:18]1[CH:19]=[C:20]([C:21]2[O:1][N:2]=[C:3]([C:5]3[CH:10]=[C:9]([CH3:11])[C:8]([CH2:12][CH:13]([CH3:15])[CH3:14])=[CH:7][N:6]=3)[N:4]=2)[CH:24]=[C:25]([CH3:37])[C:26]=1[O:27][CH2:28][C@@H:29]([OH:36])[CH2:30][NH:31][C:32](=[O:35])[CH2:33][OH:34])[CH3:17]참가 물질
3
실험 절차
The title compound (32 mg) is prepared by coupling and cyclizing N-hydroxy-5-isobutyl-4-methyl-pyridine-2-carboxamidine (40 mg, 193 μmol) with 3-ethyl-4-[(S)-2-hydroxy-3-(2-hydroxy-acetylamino)-propoxy]-5-methyl-benzoic acid (60 mg, 193 μmol) as described in Example 1; LC-MS: tR=0.95 min, [M+H]+=482.86.